Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Burning Rock Biotech (BNR) Research & Development (2019 - 2025)

Burning Rock Biotech has reported Research & Development over the past 7 years, most recently at -$5.0 million for Q4 2025.

  • For Q4 2025, Research & Development rose 30.29% year-over-year to -$5.0 million; the TTM value through Dec 2025 reached -$23.3 million, up 27.64%, while the annual FY2025 figure was $23.8 million, 25.19% down from the prior year.
  • Research & Development for Q4 2025 was -$5.0 million at Burning Rock Biotech, up from -$5.8 million in the prior quarter.
  • Over five years, Research & Development peaked at -$5.0 million in Q4 2025 and troughed at -$18.8 million in Q1 2022.
  • A 5-year average of -$11.2 million and a median of -$11.1 million in 2021 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: plummeted 106.08% in 2021 and later surged 39.1% in 2025.
  • Year by year, Research & Development stood at -$17.7 million in 2021, then grew by 17.36% to -$14.6 million in 2022, then increased by 29.55% to -$10.3 million in 2023, then surged by 30.56% to -$7.2 million in 2024, then surged by 30.29% to -$5.0 million in 2025.
  • Business Quant data shows Research & Development for BNR at -$5.0 million in Q4 2025, -$5.8 million in Q3 2025, and -$6.9 million in Q2 2025.